医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Selexis SA Strengthens Cell Line Development Services for Partners with Key Strategic Hires and Investment in State-of-the-Art Laboratory Equipment

2018年04月11日 PM09:00
このエントリーをはてなブックマークに追加


 

GENEVA

Selexis SA today announced it has made key strategic hires, signed its one hundredth commercial license agreement (CLA) and purchased and installed $2 million in new laboratory equipment following its acquisition by JSR Corporation in June 2017. Specifically, the company hired new employees, to be based in Geneva, the U.S. and Tokyo, in the areas of whole genome sequencing, global business development, production and operations. The state-of-the-art laboratory equipment will be housed at the company’s laboratory facility and corporate headquarters, which opened last spring in the heart of Geneva’s biotechnology hub, and will allow Selexis to serve its growing partner base.

“Getting much-needed medicines into the hands of healthcare providers quickly and as safely as possible is – and has been – paramount to Selexis. Our commercial-ready mammalian cell line is helping partners worldwide achieve their objectives with the highest quality and predictability,” said Igor Fisch, PhD, Selexis chief executive officer. “The transition of Selexis into JSR’s Life Sciences division last year strengthened our ability to help our partners develop increasingly complex biotherapeutics such as bi-specific proteins, triabodies, DARPins and novel scaffolds decorated with peptides, to name a few. Additionally, the integration of Selexis with KBI Biopharma, a subsidiary of JSR, allows the production of drug substances for clinical trials in as little as nine months as compared to traditional industry timelines of 16 to 24 months.”

Selexis’ investment in new equipment and employees is primarily directed towards the research and development of novel and proprietary technologies that will enable Selexis to deliver high expressing and stable research cell banks (RCBs) in eight to nine weeks from transfection (currently 14 weeks). Furthermore, the investment expands the Company’s capacity to analyze whole genomes using next-generation sequencing (NGS) methods. Whole-genome sequencing (WGS) provides Selexis partners new insights into the genome organization of any manufacturing mammalian cell line. Data from such WGS analysis can be used for safety intelligence during manufacturing campaigns, and in the near future, for regulatory submissions.

“We are constantly seeking ways to enhance innovation and, therefore, increase the speed at which we can deliver high performance cell lines through our SUREtechnology Platform™– without compromising stability and safety,” said Pierre-Alain Girod, PhD, Selexis chief scientific officer. “By adding critical talent and enhancing the equipment in our labs, we’re expanding our capabilities and improving our partners’ clinical success.”

In May 2017, Selexis opened a new corporate headquarters and laboratory facility that tripled its capacity to meet partner demands. The facility is located in Plan Le Ouates, a suburb of Geneva, Switzerland. In March 2018, the company executed its 100th commercial license agreement. The milestone signifies the value of Selexis’ proprietary SUREtechnology Platform, which facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein. It also provides seamless integration of the biologics development continuum, spanning discovery to commercialization.

About Selexis SA
Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology and the highly-specialized expertise that is necessary to translate scientific innovation into life-saving medicines for patients. Selexis’ SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With more than 100 partners worldwide, 97 drug products in clinical development and three commercial products utilizing Selexis-generated cell lines, the Company has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research. More information is available at www.selexis.com.

FOR MORE INFORMATION
- Web www.selexis.com
- LinkedIn www.linkedin.com/company/selexis-sa
- Twitter www.twitter.com/SelexisSA
- Facebook www.facebook.com/SelexisSA

View source version on businesswire.com: https://www.businesswire.com/news/home/20180411005354/en/

CONTACT

Media Inquiries for Selexis
Sam Brown Inc.
Mike
Beyer, +1 312-961-2502

mikebeyer@sambrown.com
or
Company
Inquiries for Selexis

Selexis SA
Robert Meister,
+1 602-953-1716

Head, Corporate Communications
robert.meister@selexis.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Urban Drinking Water Challenge 2018 Announces Winners from USA, India and Bangladesh
  • CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China
  • AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China
  • STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement
  • 新研究调查诊断性多通道睡眠检查之前采用Masimo SET®脉搏氧饱和度仪居家监测筛查唐氏综合征患儿罹患阻塞性睡眠呼吸暂停的风险